Fair enough 22M for 6 months. The last "review" was bascially paying someone to say your fees are reasonable. Oh well, unles tha major shareholder arc up there isn't going to be any change. If they get us to $2.50 I'll be happy.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025